http://rdf.ncbi.nlm.nih.gov/pubchem/reference/34947664

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Journal Article|Research Support, Non-U.S. Gov't
endingPage 305
issn 0167-6997
1573-0646
issueIdentifier 2
pageRange 296-305
publicationName Investigational New Drugs
startingPage 296
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_692e306d22210340946f33454efea383
bibliographicCitation Kang Z, Li S, Lin Y, Li Y, Mao Y, Zhang J, Lei T, Wang H, Su Y, Yang Y, Qiu J, Li W. A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors. Invest New Drugs. 2023 Mar 08;41(2):296–305. doi: 10.1007/s10637-022-01325-4.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a4d45a0fa4cedf70facda485d8d20167
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8652726324dbb0253eb35186e27a7050
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b398398008c664c3f864e08643d8f016
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ceb36df6f767c6d9733a5903d3792805
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e1dc13331bdc40e77b5b7b81be864b4c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_662f448a9fde5e2c45cbf16bd47c2de7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b162748f972c4fdb630cb0001450d325
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8ce23548f5d00686718f22ee7dbe4d9a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_95ee3439d5c9ed9c6a6010acbc3a4240
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_776b94d840e8850bc847a0c2270c7cec
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc63937ae7ab0cdd5664fe2f4730f686
date 2023-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/36884148
https://doi.org/10.1007/s10637-022-01325-4
https://pubmed.ncbi.nlm.nih.gov/PMC10140125
isPartOf https://portal.issn.org/resource/ISSN/0167-6997
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372
https://portal.issn.org/resource/ISSN/1573-0646
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors
discusses http://id.nlm.nih.gov/mesh/M0356369
http://id.nlm.nih.gov/mesh/M0193636
http://id.nlm.nih.gov/mesh/M0024701
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10931
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9672
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_714b3f52d8149c3277181d9513b93112
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cb58e6788fc9a69c674bb00f98bffc14
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_6848c4b6309d271cba760b85ca82568b
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1466772cb1e0216a97b90e84b70acebf
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8102
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7839

Total number of triples: 46.